Beddoe and Connor buying at SQI Diagnostics (SQD)

Beddoe and Connor buying at SQI Diagnostics (V:SQD)

Clive Beddoe, a Director and 10% Holder, acquired 14,814,815 Common Shares on an indirect ownership basis for registered holder Hanover Investments Corporation Ltd. at a price of $0.090 through a prospectus or prospectus exempt offering on February 14th, 2020. The insider also acquired 14,814,815 Warrants with an exercise price of $0.120 for five years. This represents a $1,333,333 investment into the company's shares and an account share holdings change of 26.8%.

Gerald R. Connor, a Director and 10% Holder, also acquired 14,814,815 Common Shares and 14,814,815 Warrants on a direct ownership basis. This represents an account share holdings change of 29.2%.

SQI Diagnostics is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

SQI Diagnostics Inc (SQI) is a Canada-based diagnostics company. The Company develops multiplexed tests and automated systems for customers needing to measure a range of biomarkers in blood or other common sample types. It offers three different platforms sqidlite, sqid x and the siqdworks to run and analyze its microarray plates. Its Ig_plex microarrays have the ability to discriminate between individual isotypes of antibodies and antigens and proteins within a single well of a microarray. Its Ig_plex CHEX technology provides multiple in-microarray checks. It has three areas of focus: Testing for the drug development industry, Animal health testing, Human disease testing or deoxyribonucleic acid (DNA) diagnostic testing. In drug development testing, SQI provides technology and equipment for blood testing in clinical trials and pre-clinical research for developing various drugs. It applies its multiplexing technology to diagnostic tests used for customers in the animal health segment.